Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1*
The REDEFINE clinical programme is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 112
Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association's (ADA) 85th Scientific Sessions and published in NEJM.
'In REDEFINE 1, participants saw significant and clinically meaningful weight loss under a protocol that allowed investigators to maintain patients on a submaximal dose if deemed best for the patient. We also witnessed low, single-digit discontinuation rates due to adverse events in both REDEFINE 1 and 2,' said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. 'These results reinforce our confidence in CagriSema, and we continue to study the potential of this combination through the REDEFINE trials.'
CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analogue, cagrilintide. The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group if all patients adhered to treatment.1* When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group.1** In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI < 30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment. In the placebo group,10.2% reached that threshold at 68 weeks.1
Select confirmatory secondary endpoints showed that if all participants adhered to treatment 40.4% of those receiving CagriSema achieved a body weight reduction of ≥25%.* Additionally, 23.1% lost ≥30% of their body weight.1* When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction and 19.3% achieved ≥30% body-weight reduction.1** In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus –5.7% and –4.3% for the placebo group, respectively.1
"In REDEFINE 1, CagriSema provided weight loss in the highest range of efficacy observed with existing weight loss interventions,' said lead investigator Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham. 'Investigators were allowed some flexibility in dose adjustments to balance efficacy and safety, but regardless of dose adjustments participants lost significant weight. These findings are relatable to clinical practice, where dosing is often adjusted based on individual needs and clinical judgement.'
Safety data generated in the REDEFINE 1 and 2 trials were comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo in REDEFINE 1 and 8.4% with CagriSema versus 3% with placebo in REDEFINE 2.1,3 In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs. 39.9% with placebo), including nausea (55% vs. 12.6 %), constipation (30.7% vs. 11.6%), vomiting (26.1% vs. 4.1%) and were mostly transient and mild-to-moderate in severity.1
Results from REDEFINE 2, a phase 3 study that evaluated the efficacy and safety of CagriSema plus lifestyle interventions in adults with obesity and type 2 diabetes (T2D), were also simultaneously presented during a scientific symposium at the ADA's Scientific Sessions and published in NEJM.3 In REDEFINE 2, if all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was –15.7% with CagriSema versus –3.1% with placebo.3* When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was –13.7% with CagriSema versus –3.4% with placebo.3** A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by >5% (83.6% vs. 30.8% of participants), ≥10% (65.6% vs. 10.3%), ≥15% (43.9% vs. 2.4%), and ≥20% (22.9% vs. 0.5%;).3 The safety results from CagriSema in REDEFINE 2 were similar to those reported in REDEFINE 1.3
The REDEFINE clinical programme will continue to assess the efficacy and safety of CagriSema. Most recently, Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit occurring in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2. * Based on the trial product estimand; this estimand estimates what the effect would be if all participants adhered to treatment ** Based on the treatment policy estimand: treatment effect regardless of treatment adherence
About CagriSemaCagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg.
About the REDEFINE clinical trial programmeREDEFINE is a phase 3 clinical development programme with once-weekly subcutaneous CagriSema in obesity. REDEFINE 1 and REDEFINE 2 have enrolled approximately 4,600 adults with overweight or obesity. REDEFINE 1 was a double-blind, placebo-and active-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. REDEFINE 2 was a double-blind, randomized, placebo- and controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight.
Multiple REDEFINE clinical trials are currently underway including: REDEFINE 3, an event-driven cardiovascular outcomes phase 3 trial; REDEFINE 4 an 84-week head-to-head efficacy and safety phase 3 trial of once-weekly CagriSema versus once-weekly tirzepatide; and REDEFINE 11, a phase 3 trial with longer duration and other protocol changes compared to REDEFINE 1 and 2.
About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.4-6 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.4,6 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.7,8
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media:
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Investors:
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com
Sina Meyer +45 3079 6656 azey@novonordisk.com
Max Ung +45 3077 6414 mxun@novonordisk.com
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com
References:
Garvey WT, Blüher MD, Contreras CKO, et al. CagriSema in Adults with Overweight or Obesity. New England Journal of Medicine 2025. doi: 10.1056/NEJMoa2502081
ClinicalTrials.gov. A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. Last Accessed: June 2025. Available at: https://clinicaltrials.gov/study/NCT07011667.
Davies MJ, Harpreet S, Bajaj MD, et al. CagriSema in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine 2025.
Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69.
Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723.
Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203.
Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: https://www.cdc.gov/obesity/adult-obesity-facts/index.html.
World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023.
Attachment
PR250622-ADA-CagriSema
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
What makes the Mediterranean diet so healthy?
The Mediterranean diet has long been considered one of the healthiest dietary options for a long life. But, why is that the case? Researchers say the answer lies both in the nutritious value of the meals and in their anti-inflammatory ingredients, such as dark leafy greens and olive oil. 'The Mediterranean diet is probably one tool to keep your underlying systems in harmony with each other, and that may make you less vulnerable,' Dr. Annie Moore, a University of Colorado School of Medicine internal medicine specialist, said in a statement. Eating anti-inflammatory foods — including nuts, tomatoes, and salmon — is important to help reduce inflammation. Inflammation, which is our immune system's natural response to invaders, can be harmful when it persists. Chronic inflammation has been linked to heart disease, respiratory illness, autoimmune disease, arthritis, dementia, cancer, and other conditions, according to the Cleveland Clinic. Other foods have been tied to chronic inflammation, including those with high-fat and sugar content. "Many experimental studies have shown that components of foods or beverages may have anti-inflammatory effects," Dr. Frank Hu, a professor of nutrition and epidemiology at the Harvard School of Public Health, said. So, the next time you make a meal, what do you choose to stay Mediterranean diet-compliant? If you're choosing a protein, make it fishy. Oily fish including salmon, mackerel, and sardines are rich in omega-3 fats, which have been shown to exhibit anti-inflammatory properties. Maybe also reach for fish oil, but know that there's no convincing evidence to recommend them, according to Harvard Women's Health Watch. 'Fish oil contains omega-3 fatty acids, which are part of a healthy diet that is associated with lower levels of inflammation. Your body can't manufacture omega-3 fatty acids —eicosapentaenoic acid, docosahexaenoic acid, and alpha-linolenic acid — so it's important to get them through your diet,' Harvard Health said. Experts say to cook that fish in extra-virgin olive oil, which contains anti-oxidants that fight inflammation. One is known as oleocanthal, which 'has been shown to work like ibuprofen,' according to Harvard Health. Olive oil can help fight arthritis symptoms throughout the body, according to the Arthritis Foundation. 'Antioxidants are almost like a shield around your cells, like a blanket around them to protect them from oxidative damage,' registered dietitian Julia Zumpano explained to the Cleveland Clinic. But, it's not just olive oil that's a great source of antioxidants. As a side, reach for the greens and the beans, David Dunaief, an internist in New York, told The Washington Post. 'Dark, leafy green vegetables may lower inflammation by increasing antioxidant levels,' he said. There are many versions of a Mediterranean diet. The MIND diet, or 'Mediterranean-DASH Intervention for Neurodegenerative Delay' diet, targets the health of the aging brain with its selection. Whereas the DASH diet, or 'Dietary Approaches to Stop Hypertension' eating plan, is focused on fighting high blood pressure. Make sure to avoid ultraprocessed foods, including soda, smoked meat, chips, white bread, and others that are high in saturated fats, sodium, and sugar. Recent research has tied eating ultraprocessed food to an increased risk of lung cancer. Instead, grab a whole wheat roll, put nuts and tomatoes in a salad, and eat blueberries and other fruit for — or, at least, with — your dessert. Cherries are in season! 'Sometimes it's easier to add healthy foods than taking other foods away,' Moore said.
Medscape
2 hours ago
- Medscape
Weight Loss Diet Not Needed With Exercise for Hip OA Pain
A very-low-calorie diet and weight loss combined with exercise does not appear to offer any greater reductions in hip osteoarthritis (OA) pain compared to exercise alone, even in people who are overweight or obese. Overweight and obesity are considered risk factors for hip OA, yet there are conflicting data on whether weight loss reduces the need for hip joint replacement, researchers wrote in their August 4, 2025, report published in Annals of Internal Medicine . In this study, researchers randomly assigned 101 people in Australia with a BMI above 27 to either 1) a dietitian-supported ketogenic very low-calorie diet plus a home-based exercise program supported by regular physiotherapy consultations or 2) the exercise program alone for 6 months . All the participants were aged 50 years or older, had experienced significant hip pain for at least 3 months, and had radiographic evidence of femoral or acetabular osteophytes and joint space narrowing. Despite the very-low-calorie-diet group losing a mean 8.5% more body weight than the exercise-only group, the study found no significant difference between the two groups in the primary outcome of hip pain severity at 6 or 12 months. However, both groups did show a clinically significant reduction in hip pain severity at 6 months: a 2-point reduction on an 11-point scale in the exercise-only group and 2.8-point reduction in the diet plus exercise group. More people in the diet-plus-exercise group achieved a clinically relevant reduction in hip pain severity at 6 months than in the exercise-only group. The study also found that those in the diet group had greater improvements in hip-related quality of life at 6 months compared to the exercise-only group, which persisted to 12 months. Physiotherapist and study co-author Kim Bennell, PhD, director of the Centre for Health, Exercise and Sports Medicine at the University of Melbourne, Australia, said while the association between weight and symptoms or progression was strong with knee OA, there hadn't been many high-quality randomized controlled trials of weight loss for hip OA. 'The knee is not the hip; you can't necessarily generalize results from the knee to the hip,' Bennell told Medscape . 'We thought that it may not be as effective as you find at the knee because there may be different factors driving at the hip; biomechanical factors might be more important.' Could the Results Direct Patients to Seek Surgery Sooner? An accompanying editorial by rheumatologist Gillian Hawker, MD, of Women's College Hospital in Toronto and exercise physiologist Kristine Godziuk, PhD, of the University of California, San Francisco, raised the question of whether the use of pharmacotherapies for weight loss, such as the GLP-1 receptor agonists, might influence outcomes through changes in body composition. Bennell said further studies were needed to explore whether greater weight loss than was achieved in this study might have led to better outcomes and over a longer period. Commenting on the findings, rheumatologist Nancy E. Lane, MD, endowed professor of medicine and rheumatology and director of the Center for Musculoskeletal Health at UC Davis Health, Sacramento, California, said hip OA was much more related to underlying structural abnormalities than other forms of OA. 'There's no therapy that can make it better, because the hip joint, the shape of the hip — either the femoral head or the acetabular cup — is off and it's worn out,' Lane said to Medscape . 'There's no therapy for osteoarthritis of the hip, once it becomes painful.' While weight loss would help to place less stress on the joint, it is a much smaller issue than for other joints, and being overweight in and of itself is not a risk factor for hip replacement, Lane said. 'It was really important to know that this type of exercise and weight loss wasn't going to have an effect on the hip,' she said, pointing out that this knowledge might help people with hip OA to get surgical treatment sooner, rather than being told to lose weight first. 'But to be very clear, that that's not the case in other joints, such as the knee, where these interventions make a difference,' she said.
Yahoo
3 hours ago
- Yahoo
Scientists Discovered a Way to Reverse Time—and Possibly Erase Mistakes
Here's what you'll learn when you read this story: In the physical world, time marches in one direction, but things aren't so straight forward in the quantum realm. Researchers have discovered that it's possible to speed up, slow down, or reverse the flow of time in a quantum system. This isn't exactly time travel, but is instead implementing or reverting to different quantum states from different points in time. In the subatomic universe of quantum physics, you can achieve things considered impossible in our flesh-and-blood physical world. Things like superposition, entanglement, and even teleportation all seem possible when things go quantum. Now, scientists from the Austrian Academy of Sciences (ÖAW) and University of Vienna are adding a kind of time travel to the list. In a series of papers published on preprint servers and in various online journals (including Optica, arXiv, and Quantum), researchers including ÖAW's Miguel Navascués and University of Vienna's Philip Walther explain the possibility of speeding up, slowing down, and even reversing the flow of time within a quantum system. Navascués compares the phenomenon to different movie-watching experiences. 'In a theater [classical physics], a movie is projected from beginning to end, regardless of what the audience wants,' he told the Spanish-language newspaper El País. 'But at home [the quantum world], we have a remote control to manipulate the movie. We can rewind to a previous scene or skip several scenes ahead.' The researchers achieved this by 'evolving' a single photon as it passes through a crystal. Using an experimental device called a 'quantum switch,' the single photon of light returns to its previous state before it ever makes the journey. In a way, this is less Doc Brown-style time travel and more about reverting or otherwise altering the states of quantum particles, or 'time translation' as Navascués described in 2020. However, this isn't exactly like a rewind button on your TV because usually, viewers can see how things got from plot point A to B—just sped up and in reverse. In quantum mechanics, however, simply observing a system causes it to change, which makes it impossible to track a system's progress through time. Crucially, these rewinding protocols still work because they can be performed without knowing what the changes were or its 'internal dynamics,' according to the scientists. And this quantum time machine doesn't just go one direction—Navascués said they've also hit upon a method for going forward in evolutionary time as well. He told El País: 'To make a system age 10 years in one year, you must get the other nine years from somewhere. In a year-long experiment with 10 systems, you can steal one year from each of the first nine systems and give them all to the tenth. At the end of the year, the tenth system will have aged 10 years; the other nine will remain the same as when the experiment began.' Sadly, these sci-fi findings in the quantum world can't be sized up to send humans backward and forward in time, because a single human represents a mind-boggling amount of information to 'rejuvenate'—in fact, the scientists estimate it would take millions of years to pull it off for just one second. But for the teams at ÖAW and the University of Vienna, the point isn't jetting off to the distant future, but the ability to increase the capability of quantum processors by arming them with the possibility of reversing errors in a system. After all, if life had a rewind button, wouldn't you use it? Get the Issue Get the Issue Get the Issue Get the Issue Get the Issue Get the Issue Get the IssueGet the Issue Get the Issue You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life? Solve the daily Crossword
